MX2021011536A - Agente de edición dirigida de genes activos y métodos de uso. - Google Patents

Agente de edición dirigida de genes activos y métodos de uso.

Info

Publication number
MX2021011536A
MX2021011536A MX2021011536A MX2021011536A MX2021011536A MX 2021011536 A MX2021011536 A MX 2021011536A MX 2021011536 A MX2021011536 A MX 2021011536A MX 2021011536 A MX2021011536 A MX 2021011536A MX 2021011536 A MX2021011536 A MX 2021011536A
Authority
MX
Mexico
Prior art keywords
gene editing
methods
site
directed modifying
active gene
Prior art date
Application number
MX2021011536A
Other languages
English (en)
Inventor
Hariharan Jayaram
Eric Estrin
Jillian Astarita
Original Assignee
Spotlight Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spotlight Therapeutics filed Critical Spotlight Therapeutics
Publication of MX2021011536A publication Critical patent/MX2021011536A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan métodos y composiciones relacionados con la administración intracelular de proteínas de edición de genes. La invención hace referencia a composiciones y métodos para transportar polipéptidos de edición de genes, como Cas9 o Cas12, a una célula ex vivo o in vivo. La invención incluye un agente de edición dirigida de genes activos (TAGE) que incluye un polipéptido de unión a antígenos que se une específicamente a una molécula extracelular unida a la membrana celular y un polipéptido modificador dirigido al sitio que reconoce una secuencia de ácido nucleico. El polipéptido de unión a antígenos y el polipéptido modificador dirigido al sitio se encuentran asociados de forma estable de modo tal que el polipéptido modificador dirigido al sitio se puede internalizar en una célula que muestra la molécula extracelular unida a la membrana celular.
MX2021011536A 2019-03-22 2020-03-23 Agente de edición dirigida de genes activos y métodos de uso. MX2021011536A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962822529P 2019-03-22 2019-03-22
PCT/US2020/024289 WO2020198160A1 (en) 2019-03-22 2020-03-23 Targeted active gene editing agent and methods of use

Publications (1)

Publication Number Publication Date
MX2021011536A true MX2021011536A (es) 2022-02-11

Family

ID=72610034

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021011536A MX2021011536A (es) 2019-03-22 2020-03-23 Agente de edición dirigida de genes activos y métodos de uso.

Country Status (10)

Country Link
US (1) US20220002695A1 (es)
EP (1) EP3941515A4 (es)
JP (1) JP2022524221A (es)
CN (1) CN114040775A (es)
AU (1) AU2020248370A1 (es)
CA (1) CA3134502A1 (es)
IL (1) IL286532A (es)
MX (1) MX2021011536A (es)
SG (1) SG11202110378TA (es)
WO (1) WO2020198160A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113045666B (zh) * 2021-03-23 2021-12-07 中元汇吉生物技术股份有限公司 胃蛋白酶原ii单克隆抗体及其应用
WO2024031187A1 (en) * 2022-08-11 2024-02-15 Jenthera Therapeutics Inc. A polynucleotide-modifying enzyme comprising a peptidic recognition sequence
CN115716880A (zh) * 2022-12-07 2023-02-28 云舟生物科技(广州)股份有限公司 一种核定位荧光蛋白及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2913830C (en) * 2013-05-29 2021-06-29 Cellectis Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system
CA2959130A1 (en) * 2014-08-11 2016-02-18 The Board Of Regents Of The University Of Texas System Prevention of muscular dystrophy by crispr/cas9-mediated gene editing
EP3250693B2 (en) * 2015-01-30 2023-12-20 The Regents of The University of California Protein delivery in primary hematopoietic cells
US20170246260A1 (en) * 2016-02-25 2017-08-31 Agenovir Corporation Modified antiviral nuclease
DK3491130T3 (da) * 2016-07-28 2022-10-24 Dsm Ip Assets Bv Samlingssystem til en eukaryot celle
CA3075507A1 (en) * 2017-09-11 2019-03-14 The Regents Of The University Of California Antibody-mediated delivery of cas9 to mammalian cells
EP3958671A4 (en) * 2019-04-24 2023-01-18 Spotlight Therapeutics METHODS AND COMPOSITIONS RELATED TO NUCLEIC ACID-GUIDED NUCLEASE CELL TARGETING SCREENING

Also Published As

Publication number Publication date
SG11202110378TA (en) 2021-10-28
JP2022524221A (ja) 2022-04-28
US20220002695A1 (en) 2022-01-06
CA3134502A1 (en) 2020-10-01
EP3941515A4 (en) 2022-11-30
EP3941515A1 (en) 2022-01-26
AU2020248370A1 (en) 2021-11-11
IL286532A (en) 2021-12-01
WO2020198160A1 (en) 2020-10-01
CN114040775A (zh) 2022-02-11

Similar Documents

Publication Publication Date Title
MX2021011535A (es) Agente de edición activa de genes dirigida y métodos de uso.
MX2021011536A (es) Agente de edición dirigida de genes activos y métodos de uso.
CL2020000986A1 (es) Nuevo péptido de seq id no: 33 para el uso en la inmunoterapia contra el cáncer de pulmón, incluido el cáncer de pulmón amicrocítico y otros tipos de cáncer (divisional de la solicitud no. 201701819)
EP4036079A3 (en) Compounds and compositions for intracellular delivery of agents
MX2018010824A (es) Proteinas de union inducibles y metodos de uso.
PH12016501323A1 (en) Factor viii chimeric proteins and uses thereof
PH12019550266A1 (en) Tropism-modified recombinant viral vectors and uses thereof for the targeted introduction of genetic material into human cells
NZ750005A (en) Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof
WO2016202963A3 (en) Peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer and other cancers
DE602004018141D1 (de) Polypeptide mit bindungsaffinität für her2
MX356517B (es) Polipéptidos de fusión de serpina y métodos de uso de los mismos.
MX2020002921A (es) Anticuerpos para claudin6 y métodos para tratar el cáncer.
MX2020012777A (es) Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia y metodos para crear soportes para el uso contra el cancer de pancreas y otros tipos de cancer.
WO2015023891A3 (en) Factor viii-xten fusions and uses thereof
AU2019343184A8 (en) Compositions and methods for treating cancer with anti-CD123 immunotherapy
MX2021012047A (es) Polipeptidos de fusion de serpina y metodos para utilizar los mismos.
WO2007051063A3 (en) Gpcr expressing cell lines and antibodies
MX2020005170A (es) Formulaciones de proteinas de fusion vegfr-fc.
WO2015058173A8 (en) Stable solid units and methods of making the same
WO2020076977A3 (en) Dll3 single domain antibodies and therapeutic compositions thereof
ZA202107947B (en) Combination therapy with omomyc and an antibody binding pd-1 or ctla-4 for the treatment of cancer
EP4269562A3 (en) Antigen binding molecules and methods of use thereof
MX2021011330A (es) Anticuerpos de claudina-6 y conjugados de fármacos.
MX2021016117A (es) Complejos peptidos-mhc.
MX2021010837A (es) Receptores en linfocitos t de la proteina 1 de tumor de wilms (wt1) de alta avidez.